BIND Biosciences, Inc. Initiates Phase 1 Clinical Study of BIND-014, a First-in-Class Targeted Nanoparticle Therapeutic for Cancer
1/7/2011 9:19:18 AM
(BUSINESS WIRE)--BIND Biosciences announced today that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of BIND-014 in cancer patients. BIND-014, the first product candidate to enter clinical evaluation from BIND’s broad proprietary Medicinal Nanoengineering platform, is a targeted polymeric nanoparticle containing the cytotoxic agent, docetaxel. Docetaxel is the active ingredient in Taxotere®, which is approved in major cancer indications, including breast, prostate and lung. In preclinical cancer models, BIND-014 was shown to deliver up to 20 times more docetaxel to the tumor site than an equivalent dose of Taxotere. The increased accumulation of docetaxel at the site of disease in preclinical systems translated to marked improvements in antitumor activity and tolerability.